Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Eye inflammation caused by an allergic reaction to allergens such as pollen or mold spores, dust mites, and animal fur is known as allergic conjunctivitis. It is the body’s reaction to substances that could be potentially harmful. The eyeball has a membrane known as conjunctiva, which is vulnerable to irritation from allergens. Some of the symptoms of allergic conjunctivitis are red, itchy, watery, and burning eyes. Treatment for allergic conjunctivitis include oral medications, eye drops or immunotherapy.

The Global Allergic Conjunctivitis Market is estimated to be valued at US$ 2,486.7 million in 2021 and is expected to exhibit a CAGR of 5.4% during the forecast period (2021-2028).

Figure 1.Global Allergic Conjunctivitis Market Share (%) in Terms of Value, By Drug Class, 2021

Allergic Conjunctivitis  | Coherent Market Insights

Increasing prevalence and incidence of allergic conjunctivitis expected to drive the market growth during the forecast period.

The increase in incidence and prevalence of allergic conjunctivitis is expected to drive the global allergic conjunctivitis market growth over the forecast period. For instance, according to Clinical Epidemiology and Global Health, in India, the prevalence of allergic conjunctivitis was 12.22% where allergic conjunctivitis was reported in more males (13.44%) as compared to females (10.71%) in 2019.

request-sample

Allergic Conjunctivitis Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 2,486.7 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 5.4% 2028 Value Projection: US$ 3,592.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Antihistamines & Mast Cell Stabilizers, Corticosteroids, Others
  • By Disease Type: Mild Allergic Conjunctivitis, Severe Allergic Conjunctivitis
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Eton Pharmaceutical, Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Ocular Therapeutix, Inc., Eyevance Pharmaceuticals LLC, Alcon, Santen Pharmaceutical Co., Ltd., Auven Therapeutics, and Atopix Therapeutics Ltd.

Growth Drivers:
  • Increasing prevalence and incidence of allergic conjunctivitis
  • Key companies focusing on research and development for allergic conjunctivitis treatment
Restraints & Challenges:
  • Lack of awareness of ocular allergies
  • Adverse reaction towards allergic conjunctivitis medications

Figure 2.Global Allergic Conjunctivitis Market Share (%), By Disease Type, 2021

Allergic Conjunctivitis  | Coherent Market Insights

Key companies focusing on research and development of allergic conjunctivitis are expected to drive the market growth during the forecast period.

Key players operating in the market are focusing on development of treatments for allergic conjunctivitis, this is expected to drive the global allergic conjunctivitis market growth during the forecast period. For instance, in April 2020, Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced topline results from its Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis (AC).

Global Allergic Conjunctivitis Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 198 million infected individuals worldwide as of August 2, 2021.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the global allergic conjunctivitis market are facing major challenges on various fronts due to the COVID-19 pandemic. Major challenges include the supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.

Global Allergic Conjunctivitis Market: Restraint

The major factors that hinder growth of the global allergic conjunctivitis market include the lack of awareness of ocular allergies and its adverse reaction towards medication.

Key Players

Major players operating in the global allergic conjunctivitis market are Eton Pharmaceutical, Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Ocular Therapeutix, Inc., Eyevance Pharmaceuticals LLC, Alcon, Santen Pharmaceutical Co., Ltd., Auven Therapeutics, and Atopix Therapeutics Ltd.

More than 20% of the global population is affected by eye condition called Allergic conjunctivitis. It is an allergic reaction of the outer lining of the eyeball (conjunctiva) to particles in the environment that act as allergens to certain individuals. Dust, pollen, animal dander, and sometimes even medications are all possible allergens. The eyes become red, watery, and itchy or swollen when exposed to these allergens. Although these symptoms can look like the signs of an infection, allergic conjunctivitis is not infectious or contagious. Allergic conjunctivitis is quite common. It is just the body’s reaction to substances that it considers potentially harmful. There are different types of allergic conjunctivitis such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, giant papillary conjunctivitis, vernal kerato conjunctivitis, and atopic kerato conjunctivitis.

Market Dynamics

Key players operating in the global allergic conjunctivitis market are focusing on adoption of growth strategies such as product launch, regulatory approval, and research and development for the treatment of allergic conjunctivitis, which are expected to drive the market growth during the forecast period. For instance, in March 2020, Eyevance Pharmaceuticals, is a provider of ophthalmic products and therapies intended to address unmet medical needs, announced the U.S. launch of Zerviate (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis. Moreover, in June 2017, Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehyde toxicity, announced results from a Phase 2b clinical trial of topical ocular ADX-102 in patients with allergic conjunctivitis.

Key features of the study:

  • This report provides in-depth analysis of the Global Allergic Conjunctivitis Market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Global Allergic Conjunctivitis Market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Eton Pharmaceutical, Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Ocular Therapeutix, Inc., Eyevance Pharmaceuticals LLC, Alcon, Santen Pharmaceutical Co., Ltd., Auven Therapeutics, and Atopix Therapeutics Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The Global Allergic Conjunctivitis Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Allergic Conjunctivitis Market.

Detailed Segmentation:

  • Global Allergic Conjunctivitis Market, By Drug Class :
    • Antihistamines & Mast Cell Stabilizers
    • Corticosteroids
    • Others
  • Global Allergic Conjunctivitis Market, By Disease Type :
    • Mild Allergic Conjunctivitis
    • Severe Allergic Conjunctivitis
  • Global Allergic Conjunctivitis Market, By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Allergic Conjunctivitis Market, By Region:
    • North America
      • By Drug Class
        • Antihistamines & Mast Cell Stabilizers
        • Corticosteroids
        • Others
      •  By Disease Type
        • Mild Allergic Conjunctivitis
        • Severe Allergic Conjunctivitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Class
        • Antihistamines & Mast Cell Stabilizers
        • Corticosteroids
        • Others
      •  By Disease Type
        • Mild Allergic Conjunctivitis
        • Severe Allergic Conjunctivitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class
        • Antihistamines & Mast Cell Stabilizers
        • Corticosteroids
        • Others
      •  By Disease Type
        • Mild Allergic Conjunctivitis
        • Severe Allergic Conjunctivitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • Antihistamines & Mast Cell Stabilizers
        • Corticosteroids
        • Others
      •  By Disease Type
        • Mild Allergic Conjunctivitis
        • Severe Allergic Conjunctivitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class
        • Antihistamines & Mast Cell Stabilizers
        • Corticosteroids
        • Others
      •  By Disease Type
        • Mild Allergic Conjunctivitis
        • Severe Allergic Conjunctivitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • Antihistamines & Mast Cell Stabilizers
        • Corticosteroids
        • Others
      •  By Disease Type
        • Mild Allergic Conjunctivitis
        • Severe Allergic Conjunctivitis
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Eton Pharmaceutical *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Sun Pharmaceutical Industries Ltd
    • Novartis AG
    • Bausch & Lomb Incorporated
    • Allergan
    • Ocular Therapeutix, Inc.
    • Eyevance Pharmaceuticals LLC
    • Alcon
    • Santen Pharmaceutical Co., Ltd
    • Auven Therapeutics
    • Atopix Therapeutics Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Disease Type
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Developments
    • Epidemiology
    • PEST Analysis
    • Brand Analysis
  4. Global Allergic Conjunctivitis Market– Impact of Coronavirus (COVID-19) Pandemic
    • Economic Impact
    • Impact on Clinical Trials and Drug Development
  5. Global Allergic Conjunctivitis Market, By Drug Class, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Antihistamines & Mast Cell Stabilizers 
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  6. Global Allergic Conjunctivitis Market, By Disease Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Mild Allergic Conjunctivitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Severe Allergic Conjunctivitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  7. Global Allergic Conjunctivitis Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  8. Global Allergic Conjunctivitis Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2028
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Eton Pharmaceutical
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Novartis AG.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Bausch & Lomb Incorporated.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Allergan
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Ocular Therapeutix, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Eyevance Pharmaceuticals LLC
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Alcon
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Santen Pharmaceutical Co., Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Auven Therapeutics
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Atopix Therapeutics Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
    • Analyst Views
  10. Section
    • Research Methodology
    • About us

*Browse 27 market data tables and 31 figures on "Global Allergic Conjunctivitis Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The market size is estimated to be valued at US$ 2,486.7 million in 2021 and is expected to exhibit a CAGR of 5.4% between 2021 and 2028.
Factors such as increasing prevalence and incidence of allergic conjunctivitis, and the focus of key companies towards research and development activities with respect to allergic conjunctivitis treatment is expected to drive the market growth during the forecast period.
Antihistamines & Mast Cell Stabilizers segment is expected to hold a major market share during the forecast period.
The major factors hampering growth of the market include the lack of awareness of ocular allergies and its adverse reaction towards medication.
Major players operating in the market are Eton Pharmaceutical, Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Ocular Therapeutix, Inc., Eyevance Pharmaceuticals LLC, Alcon, Santen Pharmaceutical Co., Ltd., Auven Therapeutics, and Atopix Therapeutics Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.